|
1
|
Davis GL: Monitoring of viral levels
during therapy of hepatitis C. Hepatology. 36(Suppl 1): S145–S151.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Herrmann E, Lee JH, Marinos G, Modi M and
Zeuzem S: Effect of ribavirin on hepatitis C viral kinetics in
patients treated with pegylated interferon. Hepatology.
37:1351–1358. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ferenci P, Fried MW, Shiffman ML, Smith
CI, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G,
Dhumeaux D, et al: Predicting sustained virological responses in
chronic hepatitis C patients treated with peginterferon alfa-2a (40
KD)/ribavirin. J Hepatol. 43:425–433. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jensen DM, Morgan TR, Marcellin P, Pockros
PJ, Reddy KR, Hadziyannis SJ, Ferenci P, Ackrill AM and Willems B:
Early identification of HCV genotype 1 patients responding to 24
weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology.
43:954–960. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Morishima C, Morgan TR, Everhart JE,
Wright EC, Shiffman ML, Everson GT, Lindsay KL, Lok AS, Bonkovsky
HL, Di Bisceglie AM, et al: HALT-C Trial Group: HCV RNA detection
by TMA during the hepatitis C antiviral long-term treatment against
cirrhosis (Halt-C) trial. Hepatology. 44:360–367. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gerotto M, Dal Pero F, Bortoletto G,
Ferrari A, Pistis R, Sebastiani G, Fagiuoli S, Realdon S and
Alberti A: Hepatitis C minimal residual viremia (MRV) detected by
TMA at the end of Peg-IFN plus ribavirin therapy predicts
post-treatment relapse. J Hepatol. 44:83–87. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ghany MG, Strader DB, Thomas DL and Seeff
LB: American Association for the Study of Liver Diseases:
Diagnosis, management, and treatment of hepatitis C: An update.
Hepatology. 49:1335–1374. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Izumi N: Diagnostic and treatment
algorithm of the Japanese society of hepatology: A consensus-based
practice guideline. Oncology. 78(Suppl 1): 78–86. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jacobson IM, McHutchison JG, Dusheiko G,
Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci
P, Flisiak R, et al: ADVANCE Study Team: Telaprevir for previously
untreated chronic hepatitis C virus infection. N Engl J Med.
364:2405–2416. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Poordad F, McCone J Jr, Bacon BR, Bruno S,
Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai
N, et al: SPRINT-2 Investigators: Boceprevir for untreated chronic
HCV genotype 1 infection. N Engl J Med. 364:1195–1206. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zeuzem S, Andreone P, Pol S, Lawitz E,
Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, et
al: REALIZE Study Team: Telaprevir for retreatment of HCV
infection. N Engl J Med. 364:2417–2428. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Akuta N, Suzuki F, Hirakawa M, Kawamura Y,
Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M,
et al: Amino acid substitution in hepatitis C virus core region and
genetic variation near the interleukin 28B gene predict viral
response to telaprevir with peginterferon and ribavirin.
Hepatology. 52:421–429. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kumada H, Toyota J, Okanoue T, Chayama K,
Tsubouchi H and Hayashi N: Telaprevir with peginterferon and
ribavirin for treatment-naive patients chronically infected with
HCV of genotype 1 in Japan. J Hepatol. 56:78–84. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Welch NM and Jensen DM: Pegylated
interferon based therapy with second-wave direct-acting antivirals
in genotype 1 chronic hepatitis C. Liver Int. 35(Suppl 1): 11–17.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hayashi N, Izumi N, Kumada H, Okanoue T,
Tsubouchi H, Yatsuhashi H, Kato M, Ki R, Komada Y, Seto C, et al:
Simeprevir with peginterferon/ribavirin for treatment-naïve
hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III
trial. J Hepatol. 61:219–227. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Izumi N, Hayashi N, Kumada H, Okanoue T,
Tsubouchi H, Yatsuhashi H, Kato M, Ki R, Komada Y, Seto C, et al:
Once-daily simeprevir with peginterferon and ribavirin for
treatment-experienced HCV genotype 1-infected patients in Japan:
The CONCERTO-2 and CONCERTO-3 studies. J Gastroenterol. 49:941–953.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kumada H, Hayashi N, Izumi N, Okanoue T,
Tsubouchi H, Yatsuhashi H, Kato M, Rito K, Komada Y, Seto C, et al:
Simeprevir (TMC435) once daily with peginterferon-α-2b and
ribavirin in patients with genotype 1 hepatitis C virus infection:
The CONCERTO-4 study. Hepatol Res. 45:501–513. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sugawara K, Koushima Y, Inao M, Nakayama
N, Nagoshi S, Yakabi K, Tamano M, Asabe S, Nishikawa K, Harada Y,
Sekine C, Fukuya Y, Funyu J, Hashimoto Y and Mochida S: Multicenter
prospective study to optimize the efficacy of triple therapy with
telaprevir in patients with genotype 1b hepatitis C virus infection
according to an algorithm based on the drug Adherence, IL-28B Gene
Allele and Viral Response Trial (AG & RGT). Hepatol Res.
45:1091–1099. 2015. View Article : Google Scholar : PubMed/NCBI
|
